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CLINICAL NEEDS
Dysfunction of T cell signal transduction
is responsible for many immune-
mediated diseases.  Rotating wall vessel
(RWV) bioreactors may offer a unique
environment in which pathologies due to
signaling dysfunction can be mimicked
non-pharmacologically
GOALS
Develop a flow cytometry based assay to
rapidly measure signal transduction by T
cells cultured in an RWV bioreactor.
Market this assay as a high throughput
method for testing immune-ameliorative
drugs in the RWV
APPROACH
• The RWV bioreactor prevents signal
transduction through the T cell receptor
(TCR, Figure 1).
• Similar inhibition gives rise to many
pathological conditions (Figure 2)
This project seeks to:
1. Mechanistically define signaling-inhibition
in the RWV
2.Identify a single “reporter” enzyme within
the signaling pathway, whose activation is
representative of the entire pathway
3. Develop a flow cytometry based kit to
rapidly measure activation of this reporter
enzyme in response to stimulus administered
in the RWV
DELIVERABLES
Kit for the measurement of T cell signal
transduction in the RWV including:
• Fixation and permeabilization reagents
• Fluorophore-conjugated primary antibody to
the reporter molecule
•  Bead-immobilized antibodies to CD3 and
CD28 for stimulation of the cells
Funding Required
From concept development to
optimization of the product
Figure 1: Culture of T cells in the RWV inhibits activation (Left) by
preventing signal transduction (right)
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Figure 2. Signal transduction through the T cell receptor
(left) is impaired in several diseases (right)
Timeline
Year 1: Mechanistically define the inhibition of
T cell signal transduction in the RWV
Year 2: Correlate inhibition in the RWV to
disease states.  Identify a reporter molecule
Year 3: Final optimization of kit
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